Pfizer, Inc.
PFE · NYSE
$30.06-$0.611.99%
$30.00-$0.060.20%
PFE · NYSE
Pfizer develops, manufactures and sells prescription medicines and vaccines, earning revenue primarily from product sales. Its portfolio includes oncology treatments such as ELREXFIO and TALZENNA, as well as COVID-related products; the supplied evidence identifies declining COVID revenue as a headwind but does not give segment-level revenue contributions. Customers include healthcare providers and systems, pharmacies, governments and patients. Pfizer reported FY2025 revenue of $62.6 billion and net income of $7.8 billion, compared with $63.6 billion and $8.0 billion, respectively, in FY2024. The available figures show a large global pharmaceutical business, but do not specify employee count or sales by segment.
Pfizer fell 1.55%, from $30.42 to $29.95, over the reported week. Shares closed at $29.79 on Monday, were nearly flat Tuesday at $29.80, slipped to $29.45 Wednesday, then rebounded to $29.95 Thursday. Company news was positive rather than an evident source of the decline: Pfizer reported that ELREXFIO met the primary endpoint in a Phase 3 multiple-myeloma study, and received an expanded FDA label for TALZENNA with XTANDI. The evidence does not establish that either announcement drove trading; the stock still fell on Wednesday, when Zacks noted it declined 1.17% as the broader market gained. Thursday's recovery recovered part, but not all, of the week's decline.
Pfizer gained 3.66%, rising from $28.40 to $29.44 over the reported period, though it finished below its $29.58 close on October 16. Shares were nearly flat on October 13, then jumped to $29.21 on October 14 and climbed for two more sessions before slipping on October 19. Coverage during the period focused on competing melanoma-vaccine headlines: one report said Pfizer edged higher as Moderna fell 25% after an apparent early data leak, while another reported Pfizer up 2% as Moderna and Bristol Myers Squibb rose ahead of data. The evidence does not establish those headlines as the sole cause of Pfizer’s weekly gain, and it shows no Pfizer-specific announcement driving the move.
Pfizer rose $0.48, or 1.73%, from $27.80 to $28.28 over the supplied price window. The closes show an early dip to $27.41 on Oct. 5, a recovery through Oct. 7, a small pullback on Oct. 8 and a finish at the period high on Oct. 9. The evidence does not establish a Pfizer-specific catalyst for the gain. Available coverage instead points to mixed sector conditions: vaccine makers Novavax and Moderna sold off while Pfizer was described as holding steady, and a separate report noted money rotating into healthcare. Those headlines offer market context, but the supplied closes end before the stated week beginning Oct. 12, so they cannot be tied conclusively to this price move.
Pfizer fell 1.02% over the stated week, from $28.41 to $28.12. Shares rose to $28.67 on Sep. 25 and $28.72 on Sep. 28, held there Sep. 29, then retreated to $28.52 on Sep. 30 and $28.12 on Oct. 1, surrendering the early advance. The main company-specific development in the supplied evidence was Pfizer's Thursday report that Phase 2 tilrekimig met its primary endpoint in moderate-to-severe atopic dermatitis, with detailed results showing significant skin-clearance improvements. Shares nevertheless fell that day, but the evidence does not establish that the trial update caused the decline. No broader market catalyst or dated company-specific explanation for the net weekly move is supplied.
Pfizer rose $0.16, or 0.63%, from $25.25 to $25.41 over the week. The stock initially weakened from $25.25 on July 28 to $24.91 on July 30, then recovered modestly to $25.03 on August 3. The decisive move came on August 4, when shares gained $0.38, or roughly 1.5%, on second-quarter results that exceeded earnings and revenue estimates by 13.24% and 4.04%, respectively. Pfizer also raised the low end of its 2026 sales outlook and maintained its earnings view, although it lowered expected COVID-product revenue. The quarterly loss caused by one-time charges likely limited enthusiasm, but the supplied evidence points primarily to earnings and guidance rather than broader market factors.
